RNA silencing of integrin-linked kinase increases the sensitivity of the A549 lung cancer cell line to cisplatin and promotes its apoptosis

Molecular Medicine Reports

Volumn 12, Issue 1, 2015, Pages 960-966

  Zhao, Xiaozhen ^a   Xu, Zhenye ^a   Wang, Zhongqi ^a   Wu, Zhonghua ^a   Gong, Yabin ^a   Zhou, Lijuan ^a   Xiang, Yi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Cisplatin; Integrin linked kinase; Lentivirus; Lung cancer; RNA interference

Indexed keywords

BETA CATENIN; CISPLATIN; CYCLIN D1; GELATINASE B; GLYCOGEN SYNTHASE KINASE 3BETA; INTEGRIN LINKED KINASE; PROTEIN KINASE B; RNA; TRANSCRIPTION FACTOR AP 1; ANTINEOPLASTIC AGENT; CCND1 PROTEIN, HUMAN; CTNNB1 PROTEIN, HUMAN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INTEGRIN-LINKED KINASE; PROTEIN SERINE THREONINE KINASE;

A549 CELL LINE; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CELL CYCLE ARREST; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; GENE SILENCING; GENETIC ASSOCIATION; HUMAN; HUMAN CELL; LENTIVIRINAE; MTT ASSAY; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; WESTERN BLOTTING; CELL CYCLE CHECKPOINT; DRUG EFFECTS; DRUG RESISTANCE; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENE VECTOR; GENETICS; METABOLISM; PATHOLOGY; RESPIRATORY TRACT MUCOSA; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

LENTIVIRUS;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BETA CATENIN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; CYCLIN D1; DRUG RESISTANCE, NEOPLASM; EPITHELIAL CELLS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC VECTORS; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LENTIVIRUS; MATRIX METALLOPROTEINASE 9; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RESPIRATORY MUCOSA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 84926622084     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2015.3471     Document Type: Article

References (35)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2008. CA Cancer J Clin 58: 71-96, 2008.
3. Metro G, Chiari R, Mare M, et al: Carboplatin plus pemetrexed for platinum-pretreated, advanced non-small cell lung cancer: a retrospective study with pharmacogenetic evaluation. Cancer Chemother Pharmacol 68: 1405-1412, 2011.
4. Siddik ZH (ed): Mechanisms of action of cancer chemotherapeutic agents: DNA-interactive alkylating agents and antitumour platinum-based drugs. In: The Cancer Handbook. 1st Edition. Nature Publishing Group, London, pp1295-1313, 2002.
5. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227, 2002.
6. Bordin DL, Lima M, Lenz G, et al: DNA alkylation damage and autophagy induction. Mutat Res 753: 91-99, 2013.
7. Galluzzi L, Senovilla L, Vitale I, et al: Molecular mechanisms of cisplatin resistance. Oncogene 31: 1869-1883, 2011.
8. Cetintas VB, Kucukaslan AS, Kosova B, et al: Cisplatin resistance induced by decreased apoptotic activity in non-small-cell lung cancer cell lines. Cell Biol Int 36: 261-265, 2012.
9. Hannigan G, McDonald P, Walsh M and Dedhar S: Integrin-linked kinase: not so 'pseudo'after all. Oncogene 30: 4375-4385, 2011.
10. Takanami I: Increased expression of integrin-linked kinase is associated with shorter survival in non-small cell lung cancer. BMC Cancer 5: 1, 2005.
11. Watzka SB, Rauscher-Pötsch I, Stubenberger E, et al: Immunoreactivity of integrin-linked kinase in primary non-small-cell lung cancer and survival after curative resection. Eur J Cardiothorac Surg 38: 254-259, 2010.
12. Posch F, Setinek U, Flores RM, et al: Serum integrin-linked kinase (sILK) concentration and survival in non-small cell lung cancer: a pilot study. Clin Transl Oncol 16: 455-462, 2013.
13. Zhao M, Gao Y, Wang L, et al: Overexpression of integrin-linked kinase promotes lung cancer cell migration and invasion via NF-κB-mediated upregulation of matrix metalloproteinase-9. Int J Med Sci 10: 995-1002, 2013.
14. Chen D, Zhang Y, Zhang X, et al: Overexpression of integrin-linked kinase correlates with malignant phenotype in non-small cell lung cancer and promotes lung cancer cell invasion and migration via regulating epithelial-mesenchymal transition (EMT)-related genes. Acta Histochem 115: 128-136, 2013.
15. Gao J, Zhu J, Li HY, Pan XY, Jiang R and Chen JX: Small interfering RNA targeting integrin-linked kinase inhibited the growth and induced apoptosis in human bladder cancer cells. Int J Biochem Cell Biol 43: 1294-1304, 2011.
16. Zhu XY, Liu N, Liu W, Song SW and Guo KJ: Silencing of the integrin-linked kinase gene suppresses the proliferation, migration and invasion of pancreatic cancer cells (Panc-1). Genet Mol Biol 35: 538-544, 2012.
17. Song W, Jiang R and Zhao CM: Role of integrin-linked kinase in multi-drug resistance of human gastric carcinoma SGC7901/DDP cells. Asian Pac J Cancer Prev 13: 5619-5625, 2012.
18. Younes MN, Yigitbasi OG, Yazici YD, et al: Effects of the integrin-linked kinase inhibitor QLT0267 on squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 133: 15, 2007.
19. Dolfen D, Schottler K, Valiahdi SM, et al: Synthesis, structures and in vitro cytotoxicity of some platinum (II) complexes containing thiocarbamate esters. J Inorg Biochem 102: 2067-2071, 2008.
20. Kalra J, Warburton C, Fang K, et al: QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK) and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model. Breast Cancer Res 11: R25, 2009.
21. Persad S, Attwell S, Gray V, et al: Inhibition of integrin-linked kinase (ILK) suppresses activation of protein kinase B/Akt and induces cell cycle arrest and apoptosis of PTEN-mutant prostate cancer cells. Proc Natl Acad Sci USA 97: 3207-3212, 2000.
22. Troussard AA, McDonald PC, Wederell ED, Mawji NM, et al: Preferential dependence of breast cancer cells versus normal cells on integrin-linked kinase for protein kinase B/Akt activation and cell survival. Cancer Res 66: 393-403, 2006.
23. Lin Y, Wang Z, Liu L and Chen L: Akt is the downstream target of GRP78 in mediating cisplatin resistance in ER stress-tolerant human lung cancer cells. Lung Cancer 71: 291-297, 2011.
24. Yang X, Fraser M, Moll UM, Basak A and Tsang BK: Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Cancer Res 66: 3126-3136, 2006.
25. Peng DJ, Wang J, Zhou JY and Wu GS: Role of the Akt/mTOR survival pathway in cisplatin resistance in ovarian cancer cells. Biochem Biophys Res Commun 394: 600-605, 2010.
26. Maydan M, McDonald PC, Sanghera J, et al: Integrin-linked kinase is a functional Mn2+-dependent protein kinase that regulates glycogen synthase kinase-3β (GSK-3β) phosphorylation. PloS One 5: e12356, 2010.
27. Beurel E and Jope RS: The paradoxical pro-and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79: 173-189, 2006.
28. Watcharasit P, Thiantanawat A and Satayavivad J: GSK3 promotes arsenite-induced apoptosis via facilitation of mitochondria disruption. J Appl Toxicol 28: 466-474, 2008.
29. Ngok-Ngam P, Watcharasit P, Thiantanawat A and Satayavivad J: Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Bax oligomerization in neuroblastoma SH-SY5Y cells. Cell Mol Biol Lett 18: 58-74, 2013.
30. Ban JO, Kwak DH, Oh JH, et al: Suppression of NF-κB and GSK-3β is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact 188: 75-85, 2010.
31. Kosacka M, Piesiak P, Kowal A, Golecki M and Jankowska R: Galectin-3 and cyclin D1 expression in non-small cell lung cancer. J Exp Clin Cancer Res 30: 101-107, 2011.
32. Li R, An SJ, Chen ZH, et al: Expression of cyclin D1 splice variants is differentially associated with outcome in non-small cell lung cancer patients. Hum Pathol 39: 1792-1801, 2008.
33. Huang H, Hu YD, Li N and Zhu Y: Inhibition of tumor growth and metastasis by non-small cell lung cancer cells transfected with cyclin D1-targeted siRNA. Oligonucleotides 19: 151-162, 2009.
34. Troussard AA, Costello P, Yoganathan TN, Kumagai S, Roskelley CD and Dedhar S: The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9). Oncogene 19: 5444-5452, 2000.
35. Lakka SS, Gondi CS, Yanamandra N, et al: Inhibition of cathepsin B and MMP-9 gene expression in glioblastoma cell line via RNA interference reduces tumor cell invasion, tumor growth and angiogenesis. Oncogene 23: 4681-4689, 2004.